[对“关于文章《FINDRISC问卷在识别成人胰岛素抵抗中的诊断性能》的评论”的答复]
[Answer to "Comment on the article: "Diagnostic performance of the FINDRISC questionnaire to identify insulin resistance in adults""].
作者信息
Varela-Vega Yuline, Roy-García Ivonne Analí, Pérez-Rodríguez Marcela, Velázquez-López Lubia
机构信息
Instituto Mexicano del Seguro Social, Unidad de Medicina Familiar No.17 "Legaria", Servicio de Atención Médica Continua. Ciudad de México, México.
Instituto Mexicano del Seguro Social, Coordinación de Investigación en Salud, División de Investigación Clínica. Ciudad de México, México.
出版信息
Rev Med Inst Mex Seguro Soc. 2025 Mar 3;63(2):e5034. doi: 10.5281/zenodo.14616836.
The FINDRISC instrument has been established as a screening tool to determine the risk of developing type 2 diabetes (T2D) at 10 years. However, the established cut-off points were based on a population with a low prevalence of the disease, unlike the Mexican population in which, based on the latest ENSANUT 2022 report, the global prevalence of T2D is 18.3%. Based on this, the need arose to establish a cut-off point to identify the presence of insulin resistance in this population using the FINDRISC instrument. And, in this way, identify the population one step before the development of T2D.
芬兰糖尿病风险评分（FINDRISC）工具已被确立为一种筛查工具，用于确定10年后患2型糖尿病（T2D）的风险。然而，既定的临界点是基于该疾病低患病率的人群确定的，这与墨西哥人群不同。根据最新的2022年全国健康与营养调查（ENSANUT）报告，墨西哥T2D的总体患病率为18.3%。基于此，有必要确定一个临界点，以便使用FINDRISC工具识别该人群中胰岛素抵抗的存在。并以此方式，在T2D发生前一步识别出该人群。
Zotero 插件